Gene therapy company Spark Therapeutics has published data showing its one-time treatment can almost entirely eliminate bleeds in patients with haemophilia B. The news confirms Spark as a frontrunner in the groundbreaking field, where it is poised to gain the…
Clovis PARP drug gets fast US review in new ovarian cancer use
The FDA has promised a fast review for expanded use of Clovis Oncology’s ovarian cancer pill Rubraca, that could bring it up to speed with a rivals from AstraZeneca and Tesaro. Clovis wants approval for its Rubraca (rucaparib) twice-daily pill…
